Dr. Judy Mikovits, PhD

Dr. Mikovits earned her BA in Chemistry with a specialization in biology from the University of Virginia in 1980 and her PhD in biochemistry and molecular biology from George Washington University in 1992. Upon graduation from the University of Virginia, she went directly to the National Cancer Institute in Frederick Maryland where she developed purification methods for Interferon alpha. It was this interferon, which was used in the first immune therapy treatment for hairy cell leukemia in 1986. In 1986-7, prior to enrolling in graduate school, she went to Upjohn Pharmaceuticals in Kalamazoo Michigan to develop production methods to insure biological materials manufactured using human blood products were free of contamination from HIV-1. Her PhD thesis defense titled "Negative Regulation of HIV Expression in Monocytes" changed the paradigm for therapeutic treatment of HIV. For this work, she was awarded the graduate student of the year in 1991.

In 2001, Dr. Mikovits moved back to industry where she developed multiplex diagnostic epigenetic and proteomics expression technologies for the prevention and treatment of Cancer and prediction of Immune Related Adverse Events to chemotherapy/immune therapy in susceptible populations.

In 2006, she became attracted to the plight of families with neuroimmune diseases including myalgic encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Autism Spectrum Disorders (ASD). Dr. Mikovits co-founded and developed the first neuroimmune translational research institute dedicated to understanding the pathophysiology and treatment of Neuroimmune diseases [ME/CFS, ASD, Parkinson's Disease (PD), Neuroborreliosis/Chronic Lyme Disease (CLD), Alzheimer's Disease (AD), Multiple System Atrophy (MSA) among others]. In five short years, Dr. Mikovits won more than 6 million dollars of NIH/DOD competitive funding in grants and contracts for this program demonstrating the relationship between environmentally acquired immune dysfunction, chronic inflammation and these diseases.

Her pioneering work during her twenty-year career at the National Cancer Institute includes the discovery of the modulation of DNA methylation machinery by human retroviral infection and the

development of the concept of inflammatory cytokines and chemokine signatures of infection and disease, which was first published in 1999, when she directed the Laboratory of Antiviral Drug Mechanisms in developing therapeutics and diagnostics for HIV/AIDS and AIDS associated malignancies. These are therapies that are still standard of care twenty-five years later and credited with saving millions of deaths from HIV/AIDS.

In her thirty-five-year quest to understand and treat chronic diseases, she has co-authored seminal papers culminating at least a decade of research in each of four fields: immunology, natural products chemistry, epigenetics, and HIV/AIDs drug development. In addition to more than 50 peer reviewed publications and book chapters, Dr. Mikovits holds patent # WO 2012061790 A1. "Combination Therapy for Prostate Cancer using Botanical Compositions and Bicalutamide" and authored the book, Plague.

The formation of M.A.R.C. Inc. in 2016 with colleague, Dr. Frank Ruscetti, has afforded Dr. Mikovits the opportunity to come full-circle back to her first love, natural products chemistry. M.A.R.C. Inc. is a consulting company focused on education for prevention and treatment autoimmune/auto-inflammatory diseases resulting from drugs and environmental toxins. Her heart and passion is to focus on natural products chemistry and plant based drug therapies. Her current focus is on medical cannabis with breakthroughs in understanding of the pathophysiology of neuroimmune diseases as acquired endocannabinoid immune dysfunction (AEIDS).

Mikovits 2019 Short Bio

In her thirty-five-year quest to understand and treat chronic diseases, she has co-authored seminal papers culminating at least a decade of research in each of four fields: immunology, natural products chemistry, epigenetics, and HIV/AIDs drug development. In addition to more than 50 peer reviewed publications and book chapters, Dr. Mikovits holds patent # WO 2012061790 A1. "Combination Therapy for Prostate Cancer using Botanical Compositions and Bicalutamide" and authored the books, Plague and Plague of Corruption. 

Wepage: http://plaguethebook.com/

Judy is a regular guest on the Declare Your Independence with Ernest Hancock Radio Show, coming on the show every other week (since 2016) to provide great information on what is going on in the vaccine industry, health and medical industry, legislative matters pertaining to vaccines, personal choice, and informed consent, etc...https://www.freedomsphoenix.com/Guest-Page.htm?No=01359

.  .  .

REGISTER NOW for the Vaccine Education Summit - New Hampshire, held on Sunday June 7th, 2020 @ The Executive Court Banquet Facility

Register Now for the VES 2020 - New Hampshire!

Vaccine Education Summit New Hampshire

VES 2020 New Hampshire - 1 Early Bird Ticket - Includes Lunch $80.00 USD

Early Bird Special $80 - Includes Lunch (prices go up April 20th, 2020)

Confirmed Speakers:

*Del Bigtree

*Dr Judy Mikovits

*Dr Sherri Tenpenny

Please stay tuned for updates at VaccineEducationSummit.com. You can go there now to see all the awesome speakers from previous summits (2016 and 2019)...

Join us to hear from those in the science, medical and legal communities as they speak on the topic of vaccines. 

========================================================

VES 2020 Location:

The Executive Court Banquet Facility

1199 S Mammoth Road

Manchester, NH  03109

Click Here for Map

Hotel Accommodations:

BEST WESTERN PLUS Executive Court Inn

13500 S Willow Street

Manchester, NH  03103

Click Here for Map

Click on the link, below, to reserve your room now! (VaccineEducationSummit Price $130 per night)

HOTEL ROOM RESERVATIONS